Starling Oncology enters the final week of August with an unusual divergence: the stock has pulled back nearly 5% over the week to $6.17, yet the dominant insider in the register has spent the past three months buying every meaningful dip.
The most striking feature of the current setup is the persistence of insider accumulation from the company's largest shareholder. Jorey Chernett, who controls just over 10% of the company, has bought shares in at least five separate tranches since early June — at prices ranging from $4.75 to $6.54 — accumulating roughly 75,000 shares across those purchases. The net 90-day insider balance tells the same story: the registry shows a net buy of approximately 421,000 shares worth around $2.6 million. Against that, the Non-Executive Vice Chairman Brad Hively sold just under 299,000 shares on August 21 at $6.51, a transaction worth roughly $1.9 million. The CMO also trimmed modest positions in July. The net balance still leans positive, but the Hively sale — the largest single insider transaction in the window — is worth monitoring. Chernett's pattern looks like deliberate price-level accumulation; Hively's block looks more like diversification.
Short interest has been the quiet subplot of this week's moves. Bears have actually been pulling back. SI dropped roughly 7.7% over the week to around 6.9% of the free float — still a meaningful level, but the direction of travel is clearly toward cover rather than build. Borrowing conditions confirm bears face no urgency: cost to borrow has eased to just 0.42%, the lowest reading in the 30-day window, and borrow availability is extraordinarily loose at 1,529% — meaning there are roughly fifteen shares available to borrow for every one currently lent out. That is far above the 52-week tightest reading of 223%. The ORTEX short score has slid from 49.6 at its recent peak on August 20 to 46.6 now, reflecting the unwind. Together, these readings suggest short sellers are not a near-term source of pressure, and any residual bearish thesis is being quietly wound down.
Options positioning reinforces the picture of a market not particularly on edge. The put/call ratio is running at 0.07, slightly below its 20-day average of 0.075 and well away from defensive territory. The 52-week high in the PCR was just 0.13, which already signals this is a name where downside hedging has never been especially heavy. With the z-score near zero, there is no directional signal worth reading into the options market this week.
On the Street, the single analyst consensus carries a mean price target of $9.00 against a current price of $6.17, implying roughly 46% upside — though the data is around three weeks old and there have been no recent target changes on file. The bull case centres on the specialty pharmacy segment's 41.6% revenue growth and expected margin expansion as contracts mature and the Helios partnership scales. Bears point to the clinical trials segment's 71.4% revenue collapse and the razor-thin 0.1% EBITDA margin as evidence that the headline growth story is narrow and fragile. The EV/EBITDA multiple has compressed about 22% over the past 30 days to 33.5x, partly reflecting the stock's 25% gain over the same period without a commensurate EBITDA re-rate. Institutional flows show BlackRock and State Street adding in July, while M33 Growth trimmed 1.8 million shares — a notable reduction from a venture-aligned holder that suggests some early-stage capital rotation.
The next scheduled earnings date is November 11. With short sellers in retreat, borrow conditions loose, and the largest shareholder still accumulating, the setup heading into that release will be shaped largely by whether the specialty pharmacy growth trajectory holds — and whether the clinical trials drag becomes the headline or the footnote.
See the live data behind this article on ORTEX.
Open STLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
